The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

NCT04403009 | Completed

• 1 other identifier: YLS2020(112)
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 2

Brief Summary

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Conditions

Coronavirus Disease 2019; Character of the Severe Patients

Outcome Measures

Primary Outcomes (12)

• Lymphocyte cell

  the counting of Lymphocyte(counts/L)

  2 month

• d-dimer

  d-dimer（mg/L）

  2 month

• PLT

  the counting of Platelets（(counts/L)）

  2 month

• CRP

  the level of C-reactive protein (mg/uL)

  2 month

• LDH

  lactate dehydrogenase ( U/L)

  2 month

• CK

  creatine kinase (U/L)

  2 month

• PT

  prothrombin time(second)

  2 month

• ALT

  alanine aminotransferase(U/L)

  2 month

• AST

  aspartate aminotransferase(U/L)

  2 month

• NK cell

  natural killer cell(counts/L)

  2 month

• PCT

  procalcitonin（ng/ml）

  2 month

• IL-6

  interleukin-6(mg/L)

  2 month

Secondary Outcomes (1)

• the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases

  2 months

Other Outcomes (1)

• SPO2

  2 month

Study Arms (2)

the nonsevere Coronavirus Disease 2019 Patients

Other: no intervention

the severe Coronavirus Disease 2019 Patients

Other: no intervention

Interventions

no intervention OTHER

no intervention

the nonsevere Coronavirus Disease 2019 Patients; the severe Coronavirus Disease 2019 Patients

Eligibility Criteria

• Age: 20 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients with Coronavirus Disease 2019

You may qualify if:

• The patients with Coronavirus Disease 2019
• Positive result on real-time reverse-transcriptase-polymerase-chain-reaction
• Positive result on chest computed tomography

Sponsors & Collaborators

• The First Affiliated Hospital of Guangzhou Medical University: lead

Study Sites (2)

The First Affiliated Hospital of Guangzhou Medical University

Guanzhou, Guangdong, 520120, China

Location

Hankou Hospital

Wuhan, Hubei, 430014, China

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• jianheng zhang, MD

  First Afiliated hospital of Guangzhou medical university

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 21, 2020
• First Posted: May 27, 2020
• Study Start: February 1, 2020
• Primary Completion: June 6, 2020
• Study Completion: June 20, 2020
• Last Updated: March 7, 2023

Record last verified: 2023-03

Locations

CN (2)